Skip to main content
Premium Trial:

Request an Annual Quote

John Gordon, David Schwartz, Court Turner, Stewart Noble, Andy Shiau


John Gordon has become vice president of worldwide human resources of Millipore, the company said last week. Prior to joining Millipore, he was a consultant, and before that, corporate vice president of human resources for Sentara. Gordon holds an MBA from Columbia University and a BSc from the London School of Economics.

David Schwartz will start his appointment as new director of the National Institute of Environmental Health Sciences and the National Toxicology Program on May 23, NIH said yesterday. He was named director of these institutes last fall. Schwartz comes to NIH from Duke University, where he is director of the pulmonary, allergy, and critical care division and vice chair of research in the department of medicine. He holds an MD from the University of California San Diego, an MPh from Harvard School of Public Health, and a BA in biology from the University of Rochester.

Court Turner has been promoted to vice president of strategic alliances and senior legal counsel, Stewart Noble to vice president of discovery, and Andy Shiau to director of biology of Kalypsys, the San Diego-based company said last week.

Turner, who joined Kalypsys in 2002 as director of legal affairs, holds a law degree from the University of San Diego and a degree in psychology from San Diego State University. Noble, who came to Kalypsys in 2003 as director of chemistry, holds PhD and bachelor's degrees in chemistry from the University of Birmingham in England. Shiau, a group leader at Kalypsys since last year, holds a PhD in chemistry from the University of California at San Francisco and a bachelor's degree in molecular and cell biology from the University of California at Berkeley.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more